[Adverse effects of new biological therapies for non-small-cell bronchial cancer]. / Effets indésirables des nouvelles thérapeutiques biologiques du cancer bronchique non à petites cellules.

ABSTRACT

Biological therapies targeted at bronchial cancer have a mode of action different from that of the various types of chemotherapies and are therefore associated with different types of toxicity. EGFR inhibitors cause mainly cutaneous toxicity, which can be controlled by cyclin and local care. Antiangiogenic agents increase the risk of arterial thrombosis and the risk of minor (nosebleeds) or severe (hemoptysis) bleeding. Hypertension is also a frequent side effect, generally controlled by standard antihypertensive treatment, preferably calcium channel blockers or angiotensin-converting enzyme inhibitors. Combined management by an oncologist, specialists in the relevant organs (lungs, heart, and skin) and a general practitioner is essential for optimal management of these frequent but rarely severe drug events.